Vir Biotechnology, Inc. VIR

Moby summary of Vir Biotechnology, Inc.'s Q2 2026 earnings call

Vir Biotechnology Inc (VIR) reports best-in-class HDV data, completes ECLIPSE enrollment, and extends cash runway into 2028.

SAN FRANCISCO, August 05, 2026--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the second quarter ended June 30, 2026.

Vir Biotechnology (VIR) stock is in focus after Chief Financial Officer Jason O’Byrne decided to step down effective August 3, 2026, with senior finance executive Brent Sabatini appointed as the interim principal financial officer. See our latest analysis for Vir Biotechnology. Recent trading reflects this leadership change coming at a time when Vir Biotechnology’s 30 day share price return is down 9.41% and its 90 day share price return is down 13.40%. This is despite a year to date share...

SAN FRANCISCO, July 24, 2026--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Brent Sabatini, Senior Vice President and Chief Accounting Officer, has been appointed Interim Principal Financial Officer, effective July 23. Jason O’Byrne is leaving the Company to pursue another opportunity and will remain with Vir Biotechnology through August 3 to ensure a smooth transition. The Company has initiated a comprehensive search to identify its next Chief Financial Officer.

SAN FRANCISCO, July 22, 2026--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, August 5 to provide a corporate update and discuss its financial results for the second quarter ended June 30, 2026. The conference call may be accessed on the Events & Presentations page of the Vir Biotechnology website.

Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical need, today announced end-of-treatment (EOT) results from its ongoing Phase 2b ENRICH and ENHANCE studies investigating sequential versus concurrent combination regimens of BRII-179 with elebsiran and PEG-IFNα for chronic hepatitis B virus (HBV) infection.